Edmund K. Waller

Emory University — United States

Medicine · Health Sciences

82h-index27.1kcitations899works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(266), CAR-T cell therapy research(139), Immune Cell Function and Interaction(128), Immunotherapy and Immune Responses(119), T-cell and B-cell Immunology(89)

Publications895 total

Dysbiosis and gastrointestinal GVHD: to treat or not to treat
Blood·2026Open Access
HLA Matching and Racial Disparities in Clinical Outcomes after Allogeneic Stem Cell Transplants
Transplantation and Cellular Therapy·2026
Circulating T cells Mirror Bone Marrow T cell Clonal Dynamics and Correlate with Clinical Response in Multiple Myeloma Post-Autologous HCT
Transplantation and Cellular Therapy·2026
Single-Cell Mapping of TCR:Antigen Pairs Reveals Cryptic Targets in Multiple Myeloma
Transplantation and Cellular Therapy·2026
Clinical Outcomes in Myelodysplastic Syndrome Patients Treated with Orca-T or Post-Transplant Cyclophosphamide Patients: A Registry-Based Comparison
Transplantation and Cellular Therapy·2026Open Access
Clinical Outcomes in Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients: An Observational Comparison
Transplantation and Cellular Therapy·2026
Preliminary Safety and Efficacy of Myeloablative Orca-Q in Patients with Haploidentical Donors
Transplantation and Cellular Therapy·2026
Cardiovascular and Circulatory Responses to Acute Mental Stress Among Individuals with Ischemic Cardiomyopathy
Biopsychosocial Science and Medicine·2026
Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity
Journal of Biological Chemistry·2025Open Access
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial
Blood·2025· 1 citedOpen Access
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Journal of Clinical Oncology·2025· 3 citedOpen Access
Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506
Blood·2025
MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation
Blood·2025
Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial
Blood·2025Open Access
Genetic deletion of vasoactive intestinal peptide (VIP) and PI3K signaling pathways impair CAR T cell function
Blood·2025Open Access
A chronotherapeutic approach to VIP receptor antagonist (ANT308) in anti-tumor activity
Blood·2025Open Access
Real-world effectiveness of belumosudil for chronic GVHD by line of treatment: Analysis of academic and community practice patterns
Blood·2025Open Access
High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost
Blood·2025Open Access
VIP, a novel phagocytosis checkpoint in TP53-mutated Acute Myeloid Leukemia
Blood·2025Open Access
A VPAC1/2-targeted antagonist, preferentially binds to activated T cells and enhances T cell activation
Blood·2025Open Access
page 1 of 45Next →

Frequent Co-authors

Richard T. Maziarz(11), Hillard M. Lazarus(10), Robert Peter Gale(9), Daniel J. Weisdorf(8), Mary M. Horowitz(7), Brent R. Logan(6), Corey Cutler(6), Christopher Bredeson(6), Robert J. Soiffer(6), Mehdi Hamadani(6), Samantha Jaglowski(5), David I. Marks(5), Bipin N. Savani(5), Mahmoud Aljurf(5), Wael Saber(5), Mark R. Litzow(5), Joseph P. McGuirk(4), Mukta Arora(4), Vikas Gupta(4), Steven M. Devine(4)